Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial.
Cephalalgia
; 42(4-5): 302-311, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-34541914
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Migraine Disorders
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Cephalalgia
Year:
2022
Document type:
Article
Affiliation country:
Switzerland
Country of publication:
United kingdom